by admin | Oct 29, 2026 | News
ExoCordOA, a five-year project, led by Exogenus Therapeutics and backed by Horizon Europe, brings together ten organisations spanning biotechnology, clinical development, regulation, GMP manufacturing, imaging, academia and healthcare Consortium will advance EXO-101...
by admin | Sep 15, 2026 | News
Selected among Europe’s leading life sciences executives, Exogenus Therapeutics CEO Joana Simões Correia has been named a finalist in the Women-Led Business of the Year category at the European Lifestars Awards 2026, organised by Informa Connect, the...
by admin | Jul 1, 2026 | News
€500,000 EU-funded project will advance EXO-OTO-01, Exogenus’ exosome-based therapeutic candidate for the prevention of platinum chemotherapy-induced hearing loss Programme will generate key preclinical efficacy and safety data, optimise delivery to the inner ear and...
by admin | Jan 12, 2026 | News
Exogenus Therapeutics is thrilled to announce the granting of a new patent in the United States, marking a major milestone in the company’s global expansion. This is the second region to recognize the patent family titled: “Compositions comprising small extracellular...
by admin | May 5, 2025 | News
We are pleased to announce that Exogenus Therapeutics has been granted another patent, now in Europe! This is the fifth region to recognize the patent family titled “Use of umbilical cord blood-derived exosomes for tissue repair.” This patent family has also been...
by admin | Mar 11, 2025 | News
Lonza to develop a GMP-compliant process for Exo-101 manufacturing from its Siena (IT) site Exo-101 has shown safety and efficacy in multiple pre-clinical trials, and is expected to reach patients in 2027 Basel, Switzerland and Cantanhede, Portugal, 11 March 2025 –...
